Neuphoria Therapeutics Inc. NEUP
Neuphoria Therapeutics Inc. (Nasdaq: NEUP) is a CNS/neurology/psychiatry drug developer. Its lead program, BNC210 (alpha7 nicotinic receptor negative allosteric modulator), is in Phase 2 for Post-traumatic stress disorder. Its next catalyst on record is Corporate (Scancell merger): Expected close of proposed merger with Scancell Holdings plc (2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: Corporate (Scancell merger) — Expected close of proposed merger with Scancell Holdings plc (2026). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| BNC210 | PTSD (Phase 2b ATTUNE met primary endpoint; planned Phase 2b/3 SYMPHONY paused; no active trial) | small molecule | Phase 2 |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 CNS/neurology/psychiatry companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.